Comments on the "Impact of dienogest therapy on CA125 levels, hormonal profile, and systemic inflammatory indices in endometriosis"
Year: 2026
Type: article
Abstract: Endometriosis is increasingly recognized as a systemic inflammatory condition, and dienogest is widely used as a medical treatment option. In their recent article, Bulut Arıkan and Sağsöz reported that dienogest therapy in women with endometriosis was associated with reductions in CA125, platelet-to-lymphocyte ratio (PLR), leukocyte count, and plateletcrit, alongside small increases in hemoglobin, hematocrit, and red blood cell indices. Based on these findings, the authors suggested that dienogest may exert anti-inflammatory effects and preserve endocrine homeostasis. In this letter, we highlight several methodological and interpretative issues that warrant caution. The retrospective, single-center, uncontrolled pre–post design and generally small effect sizes limit the extent to which causality and clinical significance can be inferred. Moreover, key systemic inflammatory indices such as neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, and systemic inflammation response index did not change significantly, which argues against a broad systemic anti-inflammatory effect. Finally, the proposed mechanisms for hematological improvement and endocrine safety remain speculative in the absence of detailed clinical outcomes.
DOI: 10.51271/jcogp-0078
Author: Erkan Mavigök
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7172303407